Table 3 Characteristics of the patients according to MASH status and sex.
Women (n = 217) | Men (n = 78) | p-value Women vs Men | ||||||
|---|---|---|---|---|---|---|---|---|
without MASH (n = 186) | MASH (n = 31) | P-value | without MASH (n = 52) | MASH (n = 26) | P-value | Without MASH | MASH | |
Center (Liège/Nice/Amiens/Angers/Nancy/St Grégoire/Sauvegarde-Lyon) (%) | 5.4–17.7–31.2- 3.2–12.4–11.3–18.8 | 3.2- 9.7–29.0- 6.5- 0–38.7–12.9 | < 0.01 | 13.5–17.3–34.6- 0—3.8–11.5–19.2 | 3.8–11.5–42.3- 7.7- 7.7–15.4–11.5 | 0.27 | 0.21 | 0.43 |
Age (years) | 39 (30–48) | 50 (44.5–56) | < 0.01 | 45 (36–52) | 44.5 (38.25–53.5) | 0.76 | 0.01 | 0.09 |
BMI (kg/m2) | 41.66 (39.307–46.587) | 44.82 (39.75–48.75) | 0.22 | 41.64 (39.03–46.29) | 45 (38.995–50.12) | 0.28 | 0.88 | 0.78 |
Systolic blood pressure (mmHg) | 130 (120–141) | 135 (129–153) | 0.01 | 139 (124.75–152.25) | 141 (131–145.75) | 0.91 | < 0.01 | 0.78 |
% of patients with a positive alcohol report | 7.5 | 9.7 | 0.72 | 13 | 7.7 | 0.71 | 0.18 | 1 |
AST (IU/L) | 21 (17–26) | 30 (23–38) | < 0.01 | 24 (21–33) | 37 (31–42) | < 0.01 | < 0.01 | 0.03 |
ALT (IU/L) | 23 (18–32) | 38 (30.5–59.5) | < 0.01 | 33 (27.5–52.5) | 58.5 (35.25–83.75) | < 0.01 | < 0.01 | 0.06 |
GGT (IU/L) | 26 (19–34) | 41 (30–66.5) | < 0.01 | 33 (26–51.5) | 51.5 (41.5–65) | < 0.01 | < 0.01 | 0.35 |
Alkaline phosphatases (IU/L) | 73.5 (62.75–90) | 81 (72–91) | 0.06 | 64.5 (56.25–79.5) | 72 (53–78) | 0.92 | < 0.01 | < 0.01 |
Bilirubin (mg/dL) | 0.47 (0.4–0.64) | 0.47 (0.35–0.53) | 0.16 | 0.7 (0.47–0.87) | 0.61 (0.555–0.76) | 0.91 | < 0.01 | < 0.01 |
Prothrombin Time (%) | 99 (91–100) | 100 (98.5–100) | 0.01 | 99.5 (91.25–100) | 95 (90–100) | 0.25 | 0.86 | < 0.01 |
Presence of Type 2 diabetes (%) | 12 | 58 | < 0.01 | 25 | 35 | 0.43 | 0.03 | 0.11 |
Blood glucose (mmol/L) | 5.215 (4.795–5.794) | 6.104 (5.557–7.567) | < 0.01 | 5.295 (4.895–5.904) | 5.495 (4.895–7.293) | 0.27 | 0.56 | 0.20 |
HbA1c (%) | 5.6 (5.3–5.9) | 6.4 (5.65–7.5) | < 0.01 | 5.7 (5.4–6) | 6 (5.6–6.85) | 0.07 | 0.29 | 0.33 |
Presence of Dyslipidemia (%) | 21 | 58 | < 0.01 | 35 | 42 | 0.62 | 0.06 | 0.29 |
Total cholesterol (mmol/L) | 4.7 (4.02–5.255) | 4.69 (4.11–5.058) | 0.39 | 4.42 (3.86–5.225) | 4.64 (4.21–5.47) | 0.32 | 0.40 | 0.32 |
HDL cholesterol (mmol/L) | 1.09 (0.96–1.24) | 1.26 (1.168–1.485) | < 0.01 | 0.93 (0.84–1.08) | 0.95 (0.9–1.01) | 0.91 | < 0.01 | < 0.01 |
LDL cholesterol (mmol/l) | 2.9 (2.23–3.58) | 2.77 (1.83–3.28) | 0.13 | 2.67 (1.42–3.23) | 2.98 (2.04–3.8) | 0.23 | 0.08 | 0.27 |
Triglyceride (mmol/L) | 1.37 (0.97–1.86) | 1.43 (1.08–2.14) | 0.32 | 1.51 (1.06–2.24) | 2.08 (1.36–2.81) | 0.06 | 0.09 | 0.05 |
Presence of Metabolic Syndrome (%) | 72 | 100 | < 0.01 | 83 | 83 | 1 | 0.22 | 0.10 |
Steatosis S0-S1-S2-S3 (%) | 28.5–29.0–32.8–9.7 | 0- 3.2–35.5–61.3 | < 0.01 | 13–35-35–17 | 0.0- 3.8–42.3–53.8 | < 0.01 | 0.10 | 0.79 |
Ballooning B0-B1-B2 (%) | 97.8- 2.2- 0 | 0–68-32 | < 0.01 | 100–0-0 | 0.0–96.2–3.8 | < 0.01 | 0.58 | < 0.01 |
Inflammation I0-I1-I2 (%) | 82–18- 0 | 0–61-39 | < 0.01 | 69–31- 0 | 0–88-12 | < 0.01 | 0.06 | 0.03 |
Fibrosis F0-F1-F2-F3-F4 (%) | 87.63–11.83- 0.54–0-0 | 3.3–30.0–43.3–16.7- 6.7 | < 0.01 | 69–31- 0- 0- 0 | 3.8–38.5–42.3–15.4–0 | NA | < 0.01 | 0.72 |
